Physician profile
Robert Newman
NPI 1962469874
$2,267.86
in general payments reported to CMS, 2019-2025
28 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $167 · 2021: $116 · 2022: $287 · 2023: $484 · 2024: $424 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $299.33 | 2019-2025 | Aptima, Acessa Provu System, Novasure |
| Abbvie INC. | $246.40 | 2019-2023 | |
| Organon LLC | $209.66 | 2021-2024 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $181.16 | 2019-2024 | |
| Astellas Pharma US INC | $171.21 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $169.17 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Therapeuticsmd, INC. | $145.79 | 2019-2021 | |
| Millicent US INC | $131.41 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Mayne Pharma Commercial LLC | $102.01 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $95.97 | 2019-2022 | |
| Daiichi Sankyo INC. | $71.24 | 2019 | |
| Biogen, INC. | $50.03 | 2024 | Zurzuvae |
| Minerva Surgical, INC | $44.76 | 2022-2024 | |
| Ethicon US, LLC | $42.80 | 2022-2025 | Stratafix, Dermabond Prineo, Ethicon |
| Exeltis, USA INC. | $33.34 | 2025 | Slynd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $30.87 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Shield Therapeutics INC | $27.39 | 2025 | |
| Amag Pharmaceuticals, INC. | $25.46 | 2019 | |
| Sage Therapeutics, LLC | $25.07 | 2022 | |
| Allergan, INC. | $23.53 | 2019 | |
| Duchesnay USA Incorporated | $23.41 | 2019 | |
| Novo Nordisk INC | $20.75 | 2023 | Wegovy |
| Dexcom, INC. | $17.30 | 2025 | Dexcom G6 Transmitter |
| Vertical Pharmaceuticals, LLC | $16.31 | 2019 | |
| Medicem INC. | $16.19 | 2023 | |
| Olympus America INC. | $16.09 | 2024 | Olympus |
| Myovant Sciences INC. | $15.81 | 2022 | |
| Mission Pharmacal Company | $15.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.